1. Introduction {#s0005}
===============

Glucocorticoids (GC) are a core component of current treatment protocols in T-cell acute lymphoblastic leukemia (T-ALL) and act mainly through the induction of apoptosis [@bib1]. Nevertheless, GC-resistance is common in T-ALL, which negatively impacts the overall prognosis [@bib2], [@bib3]. In addition to GC-resistance, also hypovitaminosis D appears to be associated with a decreased treatment response and a reduced prognosis in patients with hematological malignancies [@bib4]. More than 70% of children with ALL have subnormal levels of 1,25-OH~2~ vitamin D~3~ (calcitriol), which is the active form of vitamin D [@bib5]. Using primary human T-cells, we recently demonstrated that 1,25-OH~2~ vitamin D~3~ upregulates the GC receptor and increases GC induced apoptosis [@bib6]. In this study, we aimed to investigate whether there is a synergistic action of calcitriol on GC-induced apoptosis of a steroid resistant T-ALL cell line (Jurkat). Since steroid resistance is also associated with defective IL-7 signaling trough JAK/STAT, PI3K/AKT and MEK [@bib7], we furthermore investigated inhibitors of AKT (MK-2206), JAK 1/2 (ruxolitinib) and MEK (CI-1040) for possible additional synergisms between GC and calcitriol.

2. Methods {#s0010}
==========

Jurkat cells (Clone: E 6-1, kindly provided by the Department of Virology, University of Bochum, Germany; 1 ×10^7^ cells/ml) were cultured in RPMI 1640 (Invitrogen, Carlsbad, USA), 1% penicillin/streptomycin (Invitrogen), 300 mg/l L-Glutamine (Invitrogen) with 10% FCS (Sigma-Aldrich, St. Louis, USA) at stable ambient conditions (37 °C/5% CO~2~). First, cells were treated with calcitriol (100 nM, 1 µM; Medchem Express, Monmouth Junction, USA) dissolved in DMSO (final DMSO concentration in all conditions 0.25%), methylprednisolone (MP; 2.5 mM)/dexamethasone (800 µM, 1 mM; Mibe, Brehna, Germany) or the respective vehicle control for 24 h. Second, Jurkat cells were pre-incubated with calcitriol (100 nM) or vehicle control for 24 h. Jurkat cells were subsequently treated with the respective control, MP (2.5 mM), ruxolitinib (2 µM, Selleckchem, Houston, USA)/ MK-2206 (2 µM, Selleckchem)/ CI-1040 (5 µM, Selleckchem), or a combination (inhibitor + MP). After 24 h, apoptosis was evaluated by flow cytometry using Annexin V/PI staining (BD, San Jose, USA). All experiments were repeated 5--10 times. Data are presented as mean and standard error of the mean (SEM).

3. Results {#s0015}
==========

We first investigated whether calcitriol induces apoptosis in Jurkat cells. Calcitriol treatment with up to 1 µM over 24 h did not induce apoptosis in Jurkat cells (1 µM: 6.1% and 100 nM: 6.3% vs. control: 5.9%, each p \> 0.05). In contrast, MP concentrations above 0.63 mM significantly increased Jurkat cell apoptosis after 24 h ([Table 1](#t0005){ref-type="table"}) compared to the untreated control condition. To evaluate a possible synergism, Jurkat cells were co-incubated with MP (2.5 mM) and calcitriol (100 nM; 1 µM). This dual therapy resulted in a calcitriol dose-dependent 1.37--1.92-fold increase of cell death ([Fig. 1](#f0005){ref-type="fig"} A and B). This effect was not specific for MP since calcitriol also increased dexamethasone (800 µM, 1000 µM) induced apoptosis by 1.51--1.58 fold synergistically with calcitriol (1 µM, p \< 0.05; [Supplementary Fig. 1](#s0030){ref-type="sec"}).Fig. 1Synergistic effect between calcitriol and methylprednisolone on Jurkat apoptosis. **A)** Representative dot plot diagram of Jurkat cell apoptosis after 24 h incubation with DMSO-control (a), 1 µM 1,25-OH~2~ vitamin D~3~ (b), 2.5 mM MP (c) and combination therapy (d). Annexin V/PI flow cytometry staining. **B)** Percentage of apoptotic Jurkat cells (Annexin V/PI) with 1.37 (VD 100 nM) to 1.92 (VD 1 µM) fold increase of MP-induced apoptosis compared to the untreated control. n = 5, WSRT. MP: Methylprednisolone; SEM: standard error of the mean; WSRT: Wilcoxon Signed Rank Test.Fig. 1Table 1Methylprednisolone induced apoptosis after 24 h of incubation.Table 1**ConditionMean percentage of apoptotic cells (SEM)P-value (MP vs. control)Control**5.9 (0.5)**MP 6.3** **µM**6.3 (0.3)\> 0.05**MP 63** **µM**6.7 (0.3)\> 0.05**MP .63** **mM**12.1 (0.8)\< 0.05**MP 2.5** **mM**42.3 (5.0)\< 0.05**MP 3.75** **mM**77.4 (2.9)\< 0.05[^1]

Subsequently, we investigated whether the inhibition of signaling pathways involved in steroid resistance in T-ALL and treatment with MP/calcitriol have synergistic effects on the induction of apoptosis. Jurkat cells were pre-incubated with calcitriol (100 nM) or vehicle control for 24 h. They were subsequently treated with the respective control, MP, the MEK inhibitor CI-1040, the JAK 1/2 inhibitor ruxolitinib and the AKT inhibitor MK-2206 or a combination thereof.

First, CI-1040 failed to demonstrate additional effects on GC apoptosis irrespective of calcitriol supplementation (data not shown). In contrast, the JAK 1/2 inhibitor ruxolitinib showed synergistic effects with MP. However, this effect could not be increased by calcitriol pre-incubation ([Fig. 2](#f0010){ref-type="fig"}A). The inhibition of the AKT signaling pathway using MK-2206 also demonstrated a synergistic effect with MP, which further increased through calcitriol pre-incubation ([Fig. 2](#f0010){ref-type="fig"}B). Interestingly, also a synergism between calcitriol and inhibition of the AKT pathway was found, which exceeded synergistic effects of MK-2206 and MP ([Fig. 2](#f0010){ref-type="fig"}B).Fig. 2Ruxolitinib\'s and MK-2206 synergism with methylprednisolone and the effect of additional vitamin D supplementation. **A)** Ruxolitinib increases MP-induced apoptosis after 24 h pre-incubation with calcitriol (19% increase, p \< 0.05) or vehicle control (91% increase, p \< 0.01); n = 10, WSRT. **B)** AKT inhibition through MK-2206 treatment increases MP-induced apoptosis after pre-incubation with calcitriol (58%; p \< 0.05) or vehicle control for 24 h (38%; p \> 0.05); n = 5, WSRT. Abbreviations: MP: methylprednisolone; SEM: standard error of the mean. WSRT: Wilcoxon Signed Rank Test.Fig. 2

4. Discussion {#s0020}
=============

In our study, we demonstrated that the observed synergism of calcitriol and GC in primary human T-cells [@bib6] can be transferred to a model of T-ALL. This is an intriguing finding as it connects two important observations in ALL patients: (I) a reduced overall prognosis of patients with a poor response to steroids and (II) the deficiency of serum vitamin D~3~, especially of serum 1,25-OH~2~ vitamin D~3~ [@bib3], [@bib5]. We additionally investigated to what extent calcitriol acts synergistically with the inhibitors of JAK 1/2, AKT and MEK pathways, which are also relevant for steroid resistance in T-ALL [@bib7]. We identified a synergistic action of calcitriol with the AKT inhibitor MK-2206 alone as well as in combination with MP. Several vitamin D analogs have already shown the ability to inhibit AKT. Therefore, the treatment with MK-2206 and calcitriol could lead to a dual AKT inhibition, which might explain our finding [@bib8]. The presented study bears several weaknesses and should only be interpreted as a pilot investigation. 1,25-OH~2~D~3~/MP concentrations used in our in vitro analysis are higher than achieved in therapeutic situations. Additionally, conflicting evidence exists concerning the effects of 1,25-OH~2~ vitamin D~3~ on dexamethasone efficacy in several pre-B ALL cell lines [@bib9]. Nevertheless, our study clearly argues for additional research to investigate the effect of calcitriol on the therapeutic efficacy of glucocorticoids and AKT-inhibition in T-ALL patients and might have clinical implications for steroid resistant T-ALL.

Appendix A. Supplementary material {#s0030}
==================================

Supplementary Fig. 1Calcitriol synergistically increases dex-induced apootis. n = 5; WSRT. Dex: dexamethasone; SEM: standard error of the mean; WRST: Wilcoxon Signed Rank Test.Supplementary Fig. 1

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.lrr.2018.01.003](http://doi:10.1016/j.lrr.2018.01.003){#ir0005}.

[^1]: Abbreviations: MP: Methylprednisolone, SEM: Standard Error of Mean.
